Canada: Federal Court Finds Apotex infringed Merck's Product-By-Process Patent For Lovastatin

In Merck & Co. Inc. v. Apotex Inc.>, the Federal Court found Apotex to have infringed Merck's Canadian Patent No. 1,161,380 ('380 Patent), a product-by-process patent for the medicine lovastatin.

In arriving at its decision, the Court addressed key questions regarding standing, infringement and patent validity. The decision provides an interesting example of a plaintiff's successful use of DNA and circumstantial evidence in establishing two separate sources of infringement. In addition, readers should take note of the Court's finding that a pre-existing process will invalidate a product-by-process patent only where it necessarily produces the relevant product.  

This case was heard contemporaneously with another case which we will be discussing on this blog shortly.


Lovastatin, sold under the brand name Mevacor, was the first commercially-available medicine in a class of drugs known as "statins". It is used in the treatment of cardiovascular disease because it reduces the production of cholesterol in the liver, thereby minimizing plaque build-up in arterial blood vessels. The '380 Patent claims the product lovastatin when made by a process of fermentation using a micro-organism known as Aspergillus terreus.

Apotex began selling its generic version of lovastatin in 1997, and employed a production process which allegedly would not infringe the '380 Patent, as its process entailed use of a micro-organism known as Coniothyrium fuckelii. Apotex first manufactured its version of lovastatin using facilities in Winnipeg. It then transferred its C. fuckelii technology to a facility in China (Blue Treasure) in order to produce lovastatin under a joint venture agreement, subject to specific instructions that Aspergillus terreus not be used in the process.

The Allegations

Merck alleged that Apotex infringed the '380 Patent by: (1) using infringing lovastatin imported from Blue Treasure in China; (2) "salting" non-infringing lovastatin with infringing lovastatin; (3) manufacturing one batch of infringing product in Winnipeg; and (4) producing other small amounts of infringing product in Winnipeg.

Apotex's primary argument was that there had been no infringement of the '380 Patent, and that, in any event, the '380 Patent was invalid. Apotex also argued that Merck had no standing to bring its action, having allegedly assigned all its interest in the '380 Patent to an affiliate company.

After a lengthy 40-day trial and thorough consideration of the issues, the Court concluded that Merck had standing to bring the action, that the '380 Patent was valid, and that Merck's infringement allegations should succeed in part.


Relying on jurisprudence from the United States and the United Kingdom, Apotex submitted that although Merck allegedly only "licensed" the right to use the invention disclosed in the '380 Patent to an affiliate, a review of the actual words used in the agreement demonstrated that the intent and effect of the agreement was to convey the entire right, title and interest in the '380 Patent – meaning that Merck had no right to bring the action.  The Court, however, found the foreign jurisprudence relied upon by Apotex to be of little assistance, and instead relied upon Canadian contract law for the proposition that where words are clear and unambiguous, a term such as "license" should be interpreted in its normal sense to mean that no interest or property in the patent was conveyed. Merck therefore had standing to bring the action.


In order to establish infringement, Merck was required to prove on a balance of probabilities that certain volumes of lovastatin were manufactured from, or contained (through salting), Aspergillus terreus.

Merck was unable to prove its theory of "salting" by Blue Treasure. However, the Court was convinced, based upon circumstantial evidence, that Blue Treasure actually used Aspergillus terreus to produce lovastatin.  In particular, a combination of factors, including the questionable credibility of the Blue Treasure witnesses, the unreliable batch records they provided, inconsistencies in fermentation data and production levels, financial motivation to use the infringing process, and the opportunity to infringe without proper oversight, was held to support a reasonable conclusion that Blue Treasure employed a process to produce lovastatin that infringed the '380 Patent.

The Court also found, based on DNA evidence, that a single batch of lovastatin produced in Winnipeg was made using Aspergillus terreus. In making such a finding, the Court rejected Apotex's argument that the results were somehow contaminated. 

Validity of the Patent

Apotex had the burden to convince the Court, on a balance of probabilities, that the '380 Patent was invalid. In this respect, Apotex asserted that the claims of the '380 Patent were invalid for: 1) being overly broad; 2) lacking demonstrated and/or soundly predicted utility; 3) lacking novelty based on the existence of lovastatin in a traditional Asian product known as "Red Yeast Rice" (anticipation); and 4) Merck not being the first to invent lovastatin.  Each of these allegations were, however, dismissed by the Court. 

Of particular interest, the Court noted that >Red Yeast Rice would only satisfy the disclosure requirement of the test for anticipation if it could be said that it necessarily produced lovastatin. Based on the evidence, this was not the case. Instead, the evidence was that, given the significant differences in the traditional methods of producing Red Yeast Rice, the existence of lovastatin therein would be a very rare event. As such, there was no anticipation of the subject matter of the claims of the '380 Patent.

In the result, given that there was an order bifurcating the liability related issues from the remedies portion of the trial, Merck's damages are to be determined in a subsequent proceeding. 

The content of this article is intended to provide a general guide to the subject matter. Specialist advice should be sought about your specific circumstances.

To print this article, all you need is to be registered on

Click to Login as an existing user or Register so you can print this article.

In association with
Related Video
Up-coming Events Search
Font Size:
Mondaq on Twitter
Register for Access and our Free Biweekly Alert for
This service is completely free. Access 250,000 archived articles from 100+ countries and get a personalised email twice a week covering developments (and yes, our lawyers like to think you’ve read our Disclaimer).
Email Address
Company Name
Confirm Password
Mondaq Topics -- Select your Interests
 Law Performance
 Law Practice
 Media & IT
 Real Estate
 Wealth Mgt
Asia Pacific
European Union
Latin America
Middle East
United States
Worldwide Updates
Check to state you have read and
agree to our Terms and Conditions

Terms & Conditions and Privacy Statement (the Website) is owned and managed by Mondaq Ltd and as a user you are granted a non-exclusive, revocable license to access the Website under its terms and conditions of use. Your use of the Website constitutes your agreement to the following terms and conditions of use. Mondaq Ltd may terminate your use of the Website if you are in breach of these terms and conditions or if Mondaq Ltd decides to terminate your license of use for whatever reason.

Use of

You may use the Website but are required to register as a user if you wish to read the full text of the content and articles available (the Content). You may not modify, publish, transmit, transfer or sell, reproduce, create derivative works from, distribute, perform, link, display, or in any way exploit any of the Content, in whole or in part, except as expressly permitted in these terms & conditions or with the prior written consent of Mondaq Ltd. You may not use electronic or other means to extract details or information about’s content, users or contributors in order to offer them any services or products which compete directly or indirectly with Mondaq Ltd’s services and products.


Mondaq Ltd and/or its respective suppliers make no representations about the suitability of the information contained in the documents and related graphics published on this server for any purpose. All such documents and related graphics are provided "as is" without warranty of any kind. Mondaq Ltd and/or its respective suppliers hereby disclaim all warranties and conditions with regard to this information, including all implied warranties and conditions of merchantability, fitness for a particular purpose, title and non-infringement. In no event shall Mondaq Ltd and/or its respective suppliers be liable for any special, indirect or consequential damages or any damages whatsoever resulting from loss of use, data or profits, whether in an action of contract, negligence or other tortious action, arising out of or in connection with the use or performance of information available from this server.

The documents and related graphics published on this server could include technical inaccuracies or typographical errors. Changes are periodically added to the information herein. Mondaq Ltd and/or its respective suppliers may make improvements and/or changes in the product(s) and/or the program(s) described herein at any time.


Mondaq Ltd requires you to register and provide information that personally identifies you, including what sort of information you are interested in, for three primary purposes:

  • To allow you to personalize the Mondaq websites you are visiting.
  • To enable features such as password reminder, newsletter alerts, email a colleague, and linking from Mondaq (and its affiliate sites) to your website.
  • To produce demographic feedback for our information providers who provide information free for your use.

Mondaq (and its affiliate sites) do not sell or provide your details to third parties other than information providers. The reason we provide our information providers with this information is so that they can measure the response their articles are receiving and provide you with information about their products and services.

If you do not want us to provide your name and email address you may opt out by clicking here .

If you do not wish to receive any future announcements of products and services offered by Mondaq by clicking here .

Information Collection and Use

We require site users to register with Mondaq (and its affiliate sites) to view the free information on the site. We also collect information from our users at several different points on the websites: this is so that we can customise the sites according to individual usage, provide 'session-aware' functionality, and ensure that content is acquired and developed appropriately. This gives us an overall picture of our user profiles, which in turn shows to our Editorial Contributors the type of person they are reaching by posting articles on Mondaq (and its affiliate sites) – meaning more free content for registered users.

We are only able to provide the material on the Mondaq (and its affiliate sites) site free to site visitors because we can pass on information about the pages that users are viewing and the personal information users provide to us (e.g. email addresses) to reputable contributing firms such as law firms who author those pages. We do not sell or rent information to anyone else other than the authors of those pages, who may change from time to time. Should you wish us not to disclose your details to any of these parties, please tick the box above or tick the box marked "Opt out of Registration Information Disclosure" on the Your Profile page. We and our author organisations may only contact you via email or other means if you allow us to do so. Users can opt out of contact when they register on the site, or send an email to with “no disclosure” in the subject heading

Mondaq News Alerts

In order to receive Mondaq News Alerts, users have to complete a separate registration form. This is a personalised service where users choose regions and topics of interest and we send it only to those users who have requested it. Users can stop receiving these Alerts by going to the Mondaq News Alerts page and deselecting all interest areas. In the same way users can amend their personal preferences to add or remove subject areas.


A cookie is a small text file written to a user’s hard drive that contains an identifying user number. The cookies do not contain any personal information about users. We use the cookie so users do not have to log in every time they use the service and the cookie will automatically expire if you do not visit the Mondaq website (or its affiliate sites) for 12 months. We also use the cookie to personalise a user's experience of the site (for example to show information specific to a user's region). As the Mondaq sites are fully personalised and cookies are essential to its core technology the site will function unpredictably with browsers that do not support cookies - or where cookies are disabled (in these circumstances we advise you to attempt to locate the information you require elsewhere on the web). However if you are concerned about the presence of a Mondaq cookie on your machine you can also choose to expire the cookie immediately (remove it) by selecting the 'Log Off' menu option as the last thing you do when you use the site.

Some of our business partners may use cookies on our site (for example, advertisers). However, we have no access to or control over these cookies and we are not aware of any at present that do so.

Log Files

We use IP addresses to analyse trends, administer the site, track movement, and gather broad demographic information for aggregate use. IP addresses are not linked to personally identifiable information.


This web site contains links to other sites. Please be aware that Mondaq (or its affiliate sites) are not responsible for the privacy practices of such other sites. We encourage our users to be aware when they leave our site and to read the privacy statements of these third party sites. This privacy statement applies solely to information collected by this Web site.

Surveys & Contests

From time-to-time our site requests information from users via surveys or contests. Participation in these surveys or contests is completely voluntary and the user therefore has a choice whether or not to disclose any information requested. Information requested may include contact information (such as name and delivery address), and demographic information (such as postcode, age level). Contact information will be used to notify the winners and award prizes. Survey information will be used for purposes of monitoring or improving the functionality of the site.


If a user elects to use our referral service for informing a friend about our site, we ask them for the friend’s name and email address. Mondaq stores this information and may contact the friend to invite them to register with Mondaq, but they will not be contacted more than once. The friend may contact Mondaq to request the removal of this information from our database.


This website takes every reasonable precaution to protect our users’ information. When users submit sensitive information via the website, your information is protected using firewalls and other security technology. If you have any questions about the security at our website, you can send an email to

Correcting/Updating Personal Information

If a user’s personally identifiable information changes (such as postcode), or if a user no longer desires our service, we will endeavour to provide a way to correct, update or remove that user’s personal data provided to us. This can usually be done at the “Your Profile” page or by sending an email to

Notification of Changes

If we decide to change our Terms & Conditions or Privacy Policy, we will post those changes on our site so our users are always aware of what information we collect, how we use it, and under what circumstances, if any, we disclose it. If at any point we decide to use personally identifiable information in a manner different from that stated at the time it was collected, we will notify users by way of an email. Users will have a choice as to whether or not we use their information in this different manner. We will use information in accordance with the privacy policy under which the information was collected.

How to contact Mondaq

You can contact us with comments or queries at

If for some reason you believe Mondaq Ltd. has not adhered to these principles, please notify us by e-mail at and we will use commercially reasonable efforts to determine and correct the problem promptly.